Literature DB >> 11413302

Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

T Cao1, U Lazdina, I Desombere, P Vanlandschoot, D R Milich, M Sällberg, G Leroux-Roels.   

Abstract

The hepatitis B virus (HBV) core (HBc) antigen (HBcAg) is a highly immunogenic subviral particle. Studies with mice have shown that HBcAg can bind and activate B cells in a T-cell-independent fashion. By using a human peripheral blood leukocyte (hu-PBL)-Nod/LtSz-Prkdc(scid)/Prkdc(scid) (NOD/SCID) mouse model, we show here that HBcAg also activates human B cells in vivo in a T-cell-independent way. HBcAg was capable of inducing the secretion of HBcAg-binding human immunoglobulin M (IgM) in naive human B cells derived from adult human and neonatal (cord blood) donors when these hu-PBL were transferred directly into the spleens of optimally conditioned NOD/SCID mice. No such responses were found in chimeric mice that were given hu-PBL plus HBV e antigen or hu-PBL plus phosphate-buffered saline. In addition, HBcAg activated purified human B cells to produce anti-HBc IgM in the chimeric mice, thus providing evidence that HBcAg behaves as a T-cell-independent antigen in humans. However, HBcAg-activated hu-PBL from naive donors were unable to switch from IgM to IgG production, even after a booster dose of HBcAg. Production of HBcAg-specific IgG could only be induced when hu-PBL from subjects who had recovered from or had an ongoing chronic HBV infection were transferred into NOD/SCID mice. Our data suggest that humans also have a population of naive B cells that can bind HBcAg and is subsequently activated to produce HBcAg-binding IgM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413302      PMCID: PMC114358          DOI: 10.1128/JVI.75.14.6359-6366.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.

Authors:  D R Milich; A McLachlan; G B Thornton; J L Hughes
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

2.  Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.

Authors:  U Lazdina; T Cao; J Steinbergs; M Alheim; P Pumpens; D L Peterson; D R Milich; G Leroux-Roels; M Sällberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Human B cell growth and differentiation in the spleen of immunodeficient mice.

Authors:  S Depraetere; L Verhoye; G Leclercq; G Leroux-Roels
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

4.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.

Authors:  K G Tournoy; S Depraetere; R A Pauwels; G G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

6.  Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections.

Authors:  W H Gerlich; A Uy; F Lambrecht; R Thomssen
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

7.  Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis.

Authors:  M Sjogren; J H Hoofnagle
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

8.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

Review 9.  The hepatitis B virus.

Authors:  P Tiollais; C Pourcel; A Dejean
Journal:  Nature       Date:  1985 Oct 10-16       Impact factor: 49.962

10.  Transfer of a functional human immune system to mice with severe combined immunodeficiency.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

View more
  23 in total

1.  Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator.

Authors:  Peter Vanlandschoot; Freya Van Houtte; Benedikte Serruys; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

2.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

3.  Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.

Authors:  Sheryl L Gares; Karl P Fischer; Stephen E Congly; Stacey Lacoste; William R Addison; D Lorne Tyrrell; Klaus S Gutfreund
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.

Authors:  U Lazdina; T Cao; J Steinbergs; M Alheim; P Pumpens; D L Peterson; D R Milich; G Leroux-Roels; M Sällberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.

Authors:  Giane A Oliveira; Kristiane Wetzel; J Mauricio Calvo-Calle; Ruth Nussenzweig; Annette Schmidt; Ashley Birkett; Filip Dubovsky; Eveline Tierney; Christoph H Gleiter; Gabriele Boehmer; Adrian J F Luty; Michael Ramharter; George B Thornton; Peter G Kremsner; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

8.  Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus.

Authors:  Silke Arzberger; Marianna Hösel; Ulrike Protzer
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

9.  Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.

Authors:  Cuiling Yang; Na Li; Yawen Wang; Pingping Zhang; Qianqian Zhu; Fang Li; Qunying Han; Yi Lv; Ling Yu; Ping Wei; Zhengwen Liu
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

10.  Hepatitis B Core Antibody Negativity in a Chronic Hepatitis B Infected Patient: Report of an Unusual Serological Pattern.

Authors:  Vijeta Bajpai; Ekta Gupta; Naveen Kundu; Shvetank Sharma; S M Shashtry
Journal:  J Clin Diagn Res       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.